MoleculeDx Journal · Patient education

Why High-Risk Patients May Benefit From a New Generation of Liver Cancer Surveillance

Explore how Fusion-detect™ offers a new molecular approach to long-term liver cancer surveillance, potentially overcoming limitations of conventional ultrasound and AFP testing.

People at increased risk for hepatocellular carcinoma (HCC) may feel well even when a liver tumor is developing. That is why screening—more precisely called liver cancer surveillance—is planned at regular intervals rather than waiting for symptoms. Surveillance does not guarantee early detection, but it offers repeated opportunities to identify findings that need further assessment. [1,2]

Liver cancer risk does not disappear after a normal screening result

People with cirrhosis, certain forms of chronic hepatitis B, and other advanced liver diseases may remain at elevated risk of developing HCC for many years.

Because HCC can develop without obvious symptoms, ongoing surveillance is important even when patients feel well.

Current clinical guidance generally recommends surveillance at approximately six-month intervals for eligible high-risk individuals.

However, maintaining a regular testing schedule is only part of the challenge. The effectiveness of surveillance also depends on how well the chosen tests can identify early cancer.

The limitations of conventional surveillance

Traditional HCC surveillance relies on ultrasound and AFP blood testing.

Ultrasound may miss small tumors, particularly when the liver is difficult to visualize because of cirrhosis, obesity, or other factors.

AFP also has important limitations. Some patients with HCC have normal AFP concentrations, while noncancerous liver conditions can produce elevated results.

Consequently, a normal surveillance result does not always exclude an existing cancer.

These limitations have encouraged the development of more sensitive and specific biomarkers for liver cancer surveillance.

A different approach: Detecting cancer-associated molecular signals

Fusion-detect™ is MoleculeDx's proprietary blood-based approach for evaluating circulating fusion-transcript signals associated with HCC.

Instead of relying primarily on ultrasound images or AFP concentrations, Fusion-detect™ assesses a molecular pattern in blood.

The scientific basis for this approach comes from research demonstrating that selected cancer-associated fusion transcripts can be detected in serum samples from patients with HCC. [3]

MoleculeDx has also completed internal clinical validation of its Liver Cancer Fusion Predictor, supporting further evaluation of this technology as a surveillance method.

The goal is to identify molecular findings associated with possible HCC, including cancers that may be difficult to identify using conventional surveillance.

How could Fusion-detect™ fit into regular surveillance?

MoleculeDx is developing a molecular surveillance strategy for people at increased risk of HCC.

The company's proposed FDA indication includes two potential approaches:

Molecular surveillance alone: The Liver Cancer Fusion Predictor would serve as an alternative to conventional ultrasound-plus-AFP surveillance.

Molecular surveillance combined with ultrasound: Fusion-detect™ would provide molecular information alongside imaging, potentially offering a more comprehensive assessment than either approach alone.

These are proposed clinical applications under regulatory evaluation, not currently established replacements for guideline-recommended surveillance.

For eligible high-risk patients, repeated molecular testing could become part of a longitudinal surveillance strategy if supported by the necessary clinical evidence and regulatory authorization.

What happens after a positive or negative result?

Fusion-detect™ reports a positive or negative molecular surveillance finding.

A positive result indicates that a molecular pattern associated with HCC has been detected. It does not establish a definitive diagnosis. A clinician may recommend additional liver imaging and other appropriate evaluations.

A negative result indicates that the assessed molecular pattern was not detected. It does not completely exclude HCC or eliminate future cancer risk.

Individuals at increased risk should continue the surveillance schedule recommended by their healthcare professional.

Moving toward molecular surveillance

For high-risk patients, successful liver cancer surveillance requires both regular testing and methods capable of identifying concerning changes as early as possible.

Fusion-transcript analysis provides a scientifically distinct way to investigate cancer-associated signals in blood.

Fusion-detect™ represents MoleculeDx's development of this approach, with the longer-term objective of offering a molecular alternative to conventional ultrasound-plus-AFP surveillance.

This strategy has the potential to change how high-risk individuals are monitored, subject to further clinical evaluation and FDA authorization for the proposed replacement use.

Medical information disclaimer: This article provides general education and does not replace individualized medical advice. Patients should discuss surveillance decisions and abnormal results with qualified healthcare professionals.

References

1. Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965. doi:10.1097/HEP.0000000000000466.

2. Rich NE, Villanueva A, Marrero JA, Kanwal F. AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review. Gastroenterology. 2026;170:1606–1615. doi:10.1053/j.gastro.2026.03.006.

3. Yu YP, et al. Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma. Oncotarget. 2019;10:3352–3360. doi:10.18632/oncotarget.26918.

← Back to the Journal

Educational information only; consult a qualified healthcare professional. Screening does not establish or exclude a diagnosis.